Publications

Search our bibliography using the filters on the right-hand side.

Displaying 1 through 13 of 13 publications.

Patel S, Thompson W, Sivaswamy A, Khan A, Ferreira-Legere L, Lee DS, Abdel-Qadir H, Jackevicius C, Goodman S, Farkouh ME, Tu K, Kapral MK, Wijeysundera HC, Tam D, Austin PC, Fang J, Ko DT, Udell JA. Development and validation of a model to categorize cardiovascular cause of death using health administrative data. AHJ Plus. 2022 Oct;22:100207. doi: 10.1016/j.ahjo.2022.100207

Carrillo N, Malicdan MC, Leoyklang P, Shrader JA, Joe G, Slota C, Perreault J, Heiss JD, Class B, Liu CY, Bradley K, Jodarski C, Ciccone C, Driscoll C, Parks R, Van Wart S, Bayman L, Coffey CS, Quintana M, Berry SM, Huizing M, Gahl WA. Safety and efficacy of N-acetylmannosamine (ManNAc) in patients with GNE myopathy: an open-label phase 2 study. Genet Med. 2021 Nov;23(11):2067-75. doi: 10.1038/s41436-021-01259-x

Shi O, Khan AM, Rezai MR, Jackevicius CA, Cox J, Atzema CL, Ko DT, Stukel TA, Lambert LJ, Natarajan MK, Zheng ZJ, Tu JV. Factors associated with door-in to door-out delays among ST-segment elevation myocardial infarction (STEMI) patients transferred for primary percutaneous coronary intervention: a population-based cohort study in Ontario, Canada. BMC Cardiovasc Disord. 2018 Oct 29;18(1):204. doi: 10.1186/s12872-018-0940-z

Real J, Serna MC, Giner-Soriano M, Fores R, Pera G, Ribes E, Alzamora M, Marsal JR, Heras A, Morros R. Safety of cilostazol in peripheral artery disease: a cohort from a primary healthcare electronic database. BMC Cardiovasc Disord. 2018 May 8;18(1):85. doi: 10.1186/s12872-018-0822-4

Lewis MA, Stine A, Paquin RS, Mansfield C, Wood D, Rini C, Roche MI, Powell CM, Berg JS, Bailey, Jr DB. Parental preferences toward genomic sequencing for non-medically actionable conditions in children: a discrete-choice experiment. Genet Med. 2018 Feb;20(2):181-9. doi: 10.1038/gim.2017.93

Mitchell S, Roso S, Samuel M, Pladevall-Vila M. Unmet need in the hyperlipidaemia population with high risk of cardiovascular disease: a targeted literature review of observational studies. BMC Cardiovasc Disord. 2016 Apr 26;16(1):74. doi: 10.1186/s12872-016-0241-3

Pladevall M, Riera Guardia N, Margulis AV, Varas-Lorenzo C, Calingaert B, Perez-Gutthann S. Cardiovascular risk associated with the use of glitazones, metformin and sufonylureas: meta-analysis of published observational studies. BMC Cardiovasc Disord. 2016 Jan 15;16(1):14. doi: 10.1186/s12872-016-0187-5

Park EM, Deal AM, Yopp JM, Edwards T, Stephenson EM, Hailey CE, Nakamura ZM, Rosenstein DL. End-of-life parental communication priorities among bereaved fathers due to cancer. Patient Educ Couns. 2015 May;100(5):1019-23. doi: 10.1016/j.pec.2016.12.007

Varas-Lorenzo C, Margulis AV, Pladevall M, Riera-Guardia N, Calingaert B, Hazell L, Romio S, Perez-Gutthann S. The risk of heart failure associated with the use of noninsulin blood glucose-lowering drugs: systematic review and meta-analysis of published observational studies. BMC Cardiovasc Disord. 2014 Sep 26;14(1):129. doi: 10.1186/1471-2261-14-129

Arnold LM, Crofford LJ, Mease PJ, Burgess SM, Palmer SC, Abetz L, Martin SA. Patient perspectives on the impact of fibromyalgia. Patient Educ Couns. 2008 Oct;73(1):114-20.

Earnshaw SR, Wilson M, Joshi AV. The effect of recombinant activated factor VII in the treatment of intracerebral hemorrhage on health plan budgets. Managed Care Interface. 2007 Jan 1;19(11):39-45.

Earnshaw SR, Wilson MR, Joshi AV. Health plan budget impact analysis of recombinant activated factor VII (rFVIIa) in the treatment of intracerebral hemorrhage. Managed Care Interface. 2006;19(11):39-45.

Earnshaw SR, Candrilli SD, Fernandes AW, Higashi MK. A cost-effectiveness analysis of antibiotic therapy in macrolide-resistant community-acquired pneumonia. Managed Care Interface. 2005 Oct 1;18(10):36-44.